A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease

Tracy J. Doyle, Joyce S. Lee, Paul F. Dellaripa, James A. Lederer, Eric L. Matteson, Aryeh Fischer, Dana Ascherman, Marilyn K Glassberg Csete, Jay H. Ryu, Sonye K. Danoff, Kevin K. Brown, Harold R. Collard, Ivan O. Rosas

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Rheumatoid arthritis(RA) is a systemic infl ammatory disorder affecting approximately 1.3 million adults in the United States. Approximately 10% of these individuals with RA have clinically evident interstitial lung disease(RA-ILD), and an additional one-third demonstrate subclinical ILD on chest CT scan. The risk of death for individuals with RA-ILD is three times higher than for patients with RA without ILD, with a median survival after ILD diagnosis of only 2.6 years. Despite the high prevalence and mortality of RA-ILD, little is known about its molecular features and its natural history. At present, we lack a standard validated approach to the defi nition, diagnosis, risk stratification, and management of RA-ILD. In this perspective, we discuss the importance of clinical and translational research and how ongoing research efforts can address important gaps in our knowledge over the next few years. Furthermore, recommendations are made to design multicenter collaborative studies that will expedite the development of clinical trials designed to decrease the significant morbidity and mortality associated with RA-ILD.

Original languageEnglish
Pages (from-to)454-463
Number of pages10
JournalChest
Volume145
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Translational Medical Research
Interstitial Lung Diseases
Rheumatoid Arthritis
Mortality
Risk Management
Natural History
Multicenter Studies
Thorax
Clinical Trials
Morbidity
Survival
Research

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Doyle, T. J., Lee, J. S., Dellaripa, P. F., Lederer, J. A., Matteson, E. L., Fischer, A., ... Rosas, I. O. (2014). A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest, 145(3), 454-463. https://doi.org/10.1378/chest.13-2408

A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. / Doyle, Tracy J.; Lee, Joyce S.; Dellaripa, Paul F.; Lederer, James A.; Matteson, Eric L.; Fischer, Aryeh; Ascherman, Dana; Glassberg Csete, Marilyn K; Ryu, Jay H.; Danoff, Sonye K.; Brown, Kevin K.; Collard, Harold R.; Rosas, Ivan O.

In: Chest, Vol. 145, No. 3, 01.01.2014, p. 454-463.

Research output: Contribution to journalArticle

Doyle, TJ, Lee, JS, Dellaripa, PF, Lederer, JA, Matteson, EL, Fischer, A, Ascherman, D, Glassberg Csete, MK, Ryu, JH, Danoff, SK, Brown, KK, Collard, HR & Rosas, IO 2014, 'A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease', Chest, vol. 145, no. 3, pp. 454-463. https://doi.org/10.1378/chest.13-2408
Doyle, Tracy J. ; Lee, Joyce S. ; Dellaripa, Paul F. ; Lederer, James A. ; Matteson, Eric L. ; Fischer, Aryeh ; Ascherman, Dana ; Glassberg Csete, Marilyn K ; Ryu, Jay H. ; Danoff, Sonye K. ; Brown, Kevin K. ; Collard, Harold R. ; Rosas, Ivan O. / A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. In: Chest. 2014 ; Vol. 145, No. 3. pp. 454-463.
@article{cc7c7d57636d4d1fad8596aee8d7c63d,
title = "A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease",
abstract = "Rheumatoid arthritis(RA) is a systemic infl ammatory disorder affecting approximately 1.3 million adults in the United States. Approximately 10{\%} of these individuals with RA have clinically evident interstitial lung disease(RA-ILD), and an additional one-third demonstrate subclinical ILD on chest CT scan. The risk of death for individuals with RA-ILD is three times higher than for patients with RA without ILD, with a median survival after ILD diagnosis of only 2.6 years. Despite the high prevalence and mortality of RA-ILD, little is known about its molecular features and its natural history. At present, we lack a standard validated approach to the defi nition, diagnosis, risk stratification, and management of RA-ILD. In this perspective, we discuss the importance of clinical and translational research and how ongoing research efforts can address important gaps in our knowledge over the next few years. Furthermore, recommendations are made to design multicenter collaborative studies that will expedite the development of clinical trials designed to decrease the significant morbidity and mortality associated with RA-ILD.",
author = "Doyle, {Tracy J.} and Lee, {Joyce S.} and Dellaripa, {Paul F.} and Lederer, {James A.} and Matteson, {Eric L.} and Aryeh Fischer and Dana Ascherman and {Glassberg Csete}, {Marilyn K} and Ryu, {Jay H.} and Danoff, {Sonye K.} and Brown, {Kevin K.} and Collard, {Harold R.} and Rosas, {Ivan O.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1378/chest.13-2408",
language = "English",
volume = "145",
pages = "454--463",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease

AU - Doyle, Tracy J.

AU - Lee, Joyce S.

AU - Dellaripa, Paul F.

AU - Lederer, James A.

AU - Matteson, Eric L.

AU - Fischer, Aryeh

AU - Ascherman, Dana

AU - Glassberg Csete, Marilyn K

AU - Ryu, Jay H.

AU - Danoff, Sonye K.

AU - Brown, Kevin K.

AU - Collard, Harold R.

AU - Rosas, Ivan O.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Rheumatoid arthritis(RA) is a systemic infl ammatory disorder affecting approximately 1.3 million adults in the United States. Approximately 10% of these individuals with RA have clinically evident interstitial lung disease(RA-ILD), and an additional one-third demonstrate subclinical ILD on chest CT scan. The risk of death for individuals with RA-ILD is three times higher than for patients with RA without ILD, with a median survival after ILD diagnosis of only 2.6 years. Despite the high prevalence and mortality of RA-ILD, little is known about its molecular features and its natural history. At present, we lack a standard validated approach to the defi nition, diagnosis, risk stratification, and management of RA-ILD. In this perspective, we discuss the importance of clinical and translational research and how ongoing research efforts can address important gaps in our knowledge over the next few years. Furthermore, recommendations are made to design multicenter collaborative studies that will expedite the development of clinical trials designed to decrease the significant morbidity and mortality associated with RA-ILD.

AB - Rheumatoid arthritis(RA) is a systemic infl ammatory disorder affecting approximately 1.3 million adults in the United States. Approximately 10% of these individuals with RA have clinically evident interstitial lung disease(RA-ILD), and an additional one-third demonstrate subclinical ILD on chest CT scan. The risk of death for individuals with RA-ILD is three times higher than for patients with RA without ILD, with a median survival after ILD diagnosis of only 2.6 years. Despite the high prevalence and mortality of RA-ILD, little is known about its molecular features and its natural history. At present, we lack a standard validated approach to the defi nition, diagnosis, risk stratification, and management of RA-ILD. In this perspective, we discuss the importance of clinical and translational research and how ongoing research efforts can address important gaps in our knowledge over the next few years. Furthermore, recommendations are made to design multicenter collaborative studies that will expedite the development of clinical trials designed to decrease the significant morbidity and mortality associated with RA-ILD.

UR - http://www.scopus.com/inward/record.url?scp=84896755295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896755295&partnerID=8YFLogxK

U2 - 10.1378/chest.13-2408

DO - 10.1378/chest.13-2408

M3 - Article

C2 - 24590021

AN - SCOPUS:84896755295

VL - 145

SP - 454

EP - 463

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -